Numerical Simulation of Solid Tumor Blood Perfusion and Drug Delivery during the  “Vascular Normalization Window” with Antiangiogenic Therapy

<table class="table-group" width="800px"><tr class="fig-image" id="a"><td><img alt="190371.fig.003a" src="https://static.hindawi.com/articles/jam/volume-2011/190371/figures/190371.fig.003a.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(a) </b>before treatment</td></tr></table></td></tr><tr class="fig-image" id="b"><td><img alt="190371.fig.003b" src="https://static.hindawi.com/articles/jam/volume-2011/190371/figures/190371.fig.003b.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(b) </b>after treatment</td></tr></table></td></tr></table>

<table>The simulation results of blood perfusion. <svg height="15.4" id="M12" style="vertical-align:-3.3907pt" version="1.1" viewbox="0 0 14.8125 15.4" width="14.8125" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,11.112)"><path d="M619 482q0 -69 -40.5 -119t-96 -72.5t-118.5 -26.5h-44l-70 20l-31 -151q-14 -67 0.5 -83t89.5 -22l-5 -28h-287l8 28q65 7 81.5 22t29.5 83l79 398q12 56 0.5 70.5t-78.5 20.5l7 28h255q108 0 164 -43t56 -125zM524 478q0 141 -146 141q-25 0 -47 -8q-16 -6 -20.5 -13.5
t-10.5 -39.5l-43 -241q37 -13 83 -13q67 0 125.5 45t58.5 129z" id="x1D443"></path></g>
<g transform="matrix(.012,-0,0,-.012,10.875,15.187)"><path d="M244 607q0 -25 -15.5 -43t-37.5 -18q-19 0 -32 13t-13 35q0 21 15 41t39 20q20 0 32 -14t12 -34zM222 91q-29 -33 -79 -68t-75 -35q-13 0 -19 7.5t-6 31t10 65.5l62 253q5 26 -1 26q-21 0 -72 -43l-13 24q43 40 91 68t71 28q30 0 10 -78l-71 -274q-8 -30 3 -30
q16 0 76 48z" id="x1D456"></path></g>
</svg> is the interstitial fluid pressure (IFP).</table>

Journal of Applied Mathematics

fig3

Figure 3

Figure 3: Numerical Simulation of Solid Tumor Blood Perfusion and Drug Delivery during the  “Vascular Normalization Window” with Antiangiogenic Therapy 

Figure 3 | Numerical Simulation of Solid Tumor Blood Perfusion and Drug Delivery during the  “Vascular Normalization Window” with Antiangiogenic Therapy 